Reply to Wallis

To the Editor—Wallis identifies several shortcomings in previous trials that claim a therapeutic role for interferon γ (IFN-γ) in tuberculosis [1]. He also reviews a study that reports increased mortality in the IFN-γ–treated group. With this information, Wallis concludes that IFN-γ lacks any therapeutic value in tuberculosis and was rightfully concerned about our “speculation that [our] work is likely to enable future therapeutic trials of IFN-γ for tuberculosis” [1].

We reported a novel mechanism through which M. tuberculosis actively exploited IFN-γ to promote nonprotective necrotic death in human macrophages [2]. With this ability to exploit IFN-γ, M. tuberculosis might render endogenous or exogenous IFN-γ not only ineffective against M. tuberculosis but also hazardous to host macrophages. Our findings, therefore, fit Wallis’ interpretation of the data from previous IFN-γ trials. However, we also believe that the true protective effect of IFN-γ has not been determined, probably because of interfering mechanisms of M. tuberculosis, such as the ESX-1 secretion system we reported or other yet-to-be-defined mechanisms. Without a thorough understanding of
how *M. tuberculosis* interferes with IFN-γ, it might be premature to completely discard a potential protective effect of IFN-γ against *M. tuberculosis* infections. With this reasoning, we speculated that the efficacy of IFN-γ against tuberculosis might be improved by blocking the ability of *M. tuberculosis* to exploit IFN-γ.

**Notes**

**Financial support.** This work was supported by the National Institutes of Health (grant AI26170) and the Albert Einstein College of Medicine Center for AIDS Research (grant AI0-51519).

**Potential conflicts of interest.** All authors: No reported conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Ka-Wing Wong¹² and William R. Jacobs Jr³

¹Key Laboratory of Medical Molecular Virology, School of Basic Medical Sciences, Shanghai Medical College, and ²Shanghai Public Health Clinical Center, Fudan University, Shanghai, China; and ³Department of Microbiology and Immunology, Howard Hughes Medical Institute, Albert Einstein College of Medicine, Bronx, New York

**References**


Received 3 September 2013; accepted 3 September 2013.

Correspondence: William R. Jacobs Jr, PhD, Howard Hughes Medical Institute, Albert Einstein College of Medicine, 1301 Morris Park Ave, Bronx, NY 10461 (jacobsw@hhmi.org).

The Journal of Infectious Diseases 2014;209:628–9

© The Author 2013. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

DOI: 10.1093/infdis/jit556